Investor Presentaiton slide image

Investor Presentaiton

Commercialisation: Johns Hopkins COPD trial result • Has the capability of assessing regional ventilation defects, which is critical to optimising therapies. Is a repeatable lung assessment tool in a cohort of COPD patients. • Illustrates distribution of airflow within the lungs, corresponding with COPD severity. Mean Specific Ventilation (a.u.) Ventilation Heterogeneity/ Ventilation Heterogeneity By Disease Severity 200 400 600 800 1,000 1,200 Inspiration Expiration 1 2 GOLD score 4DMedical Limited | Investor Presentation | November 2022 Patient 2 Patient 1 Visit 1 RIGHT LEFT UPPER RIGHT Normalized Specific Ventilation 0 RIGHT 3 4 Normalized Specific Ventilation 0 R Upper MIDDLE Middle 4DMedical™ Visit 2 Upper LEFT Middle Lower Lower LOWER LEFT UPPER RIGHT LEFT UPPER MIDDLE LOWER Normalized Specific Ventilation 1 2 R R L MIDDLE R L LOWER 22
View entire presentation